|
124 Companies |
|
161 Products |
|
161 Products |
|
116 Mechanisms of Action |
|
11 Trials |
|
2428 News |
|
| «12345678910111213...4950» |
- | Phase classification: MAINTAIN: Micronutrients and Antioxidants in HIV Infection (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=218, Active, not recruiting, Sponsor: Ottawa Hospital Research Institute
Phase classification: P2/3 --> P=N/A
- | Phase classification: Zinc for HIV Disease Among Alcohol Users - an RCT in the Russia ARCH Cohort (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=250, Active, not recruiting, Sponsor: Boston Medical Center
Phase classification: P2/3 --> P=N/A Phase classification: P2/3 --> P=N/A
- Selzentry (maraviroc) / ViiV Healthcare
Phase classification: An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=0, No Longer Available, Sponsor: ViiV Healthcare
Phase classification: P2/3 --> P=N/A Phase classification: P4 --> P=N/A
- | prednisone / Generic mfg.
Enrollment change, Trial withdrawal: A RCT of Prednisone as Adjunctive Therapy for Hospitalized Patients With Pulmonary TB and HIV Co-infection (clinicaltrials.gov) - Apr 4, 2017
P3, N=0, Withdrawn, Sponsor: Ottawa Hospital Research Institute
Phase classification: P4 --> P=N/A N=412 --> 0 | Completed --> Withdrawn
- | emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion, Trial primary completion date: Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Adolescents (clinicaltrials.gov) - Apr 4, 2017
P2, N=149, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=412 --> 0 | Completed --> Withdrawn Active, not recruiting --> Completed | Trial primary completion date: Aug 2017 --> Mar 2016
- | Enrollment closed, Trial primary completion date, Adherence: MedCHEC: Medications for Chronic HIV: Education and Collaboration (clinicaltrials.gov) - Mar 31, 2017
P=N/A, N=348, Active, not recruiting, Sponsor: Boston University
Active, not recruiting --> Completed | Trial primary completion date: Aug 2017 --> Mar 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2012 --> Jun 2013
- | Vitekta (elvitegravir) / Japan Tobacco, Gilead
Trial primary completion date: Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants (clinicaltrials.gov) - Mar 30, 2017
P2/3, N=31, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2012 --> Jun 2013 Trial primary completion date: Feb 2017 --> Jun 2017
- | NN1213 / Novo Nordisk, Twinrix (inactivated hepatitis A and recombinant hepatitis B) / GSK, Engerix-B (hepatitis B vaccine recombinant) / GSK
Trial completion: Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth (clinicaltrials.gov) - Mar 28, 2017
P4, N=371, Completed, Sponsor: University of North Carolina, Chapel Hill
Trial primary completion date: Feb 2017 --> Jun 2017 Active, not recruiting --> Completed
- | Phase classification: A Self-Assessment Intervention for Young Adult Polydrug Users at Risk for HIV (clinicaltrials.gov) - Mar 27, 2017
P=N/A, N=750, Active, not recruiting, Sponsor: Nova Southeastern University
Active, not recruiting --> Completed Phase classification: P2 --> P=N/A
- | Trial completion, Phase classification, Enrollment change: CCRC: A Project of the Treatment of HIV Enteropathy With ImmunoLin (clinicaltrials.gov) - Mar 24, 2017
P, N=8, Completed, Sponsor: University of California, Davis
Phase classification: P2 --> P=N/A Active, not recruiting --> Completed | Phase classification: PN/A --> P | N=12 --> 8
- | Trial completion: Vitamin D Supplementation in HIV (clinicaltrials.gov) - Mar 17, 2017
P2/3, N=58, Completed, Sponsor: Children's Hospital of Philadelphia
Active, not recruiting --> Completed | Phase classification: PN/A --> P | N=12 --> 8 Active, not recruiting --> Completed
- | Trial completion, Phase classification, Enrollment change: Relationship of Tenofovir With HIV-1 Suppression in ex Vivo Tissue in Adolescents (clinicaltrials.gov) - Mar 13, 2017
P=N/A, N=13, Completed, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed Recruiting --> Completed | Phase classification: P1 --> PN/A | N=24 --> 13
- | Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Phase classification: PRO 140 for Human Immunodeficiency Virus Infection (clinicaltrials.gov) - Mar 9, 2017
P2a, N=0, Withdrawn, Sponsor: Drexel University
Recruiting --> Completed | Phase classification: P1 --> PN/A | N=24 --> 13 Phase classification: P2 --> P2a
- | valacyclovir / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2 (clinicaltrials.gov) - Mar 9, 2017
P4, N=50, Completed, Sponsor: University of Washington
Phase classification: P2 --> P2a Active, not recruiting --> Completed | N=82 --> 50 | Trial primary completion date: Sep 2011 --> Jul 2010
- | acyclovir / Generic mfg.
Trial completion, Trial primary completion date: A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 Reactivation (clinicaltrials.gov) - Mar 9, 2017
P4, N=48, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed | N=82 --> 50 | Trial primary completion date: Sep 2011 --> Jul 2010 Active, not recruiting --> Completed | Trial primary completion date: Sep 2011 --> Jul 2010
- | Phase classification: Preventative Misconception Intervention (clinicaltrials.gov) - Mar 3, 2017
P=N/A, N=120, Completed, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed | Trial primary completion date: Sep 2011 --> Jul 2010 Phase classification: P1/2 --> P=N/A
- Isentress (raltegravir) / Merck (MSD)
Phase classification: REAL: Raltegravir as Early Therapy in African-Americans Living With HIV Study (clinicaltrials.gov) - Mar 3, 2017
P1, N=38, Completed, Sponsor: David A Wohl, MD
Phase classification: P1/2 --> P=N/A Phase classification: P4 --> P1
- | Trial initiation date: Traditional Complementary and Alternative Medicine (CAM) Therapy in the Treatment of HIV/AIDS (clinicaltrials.gov) - Mar 3, 2017
P3, N=1000, Completed, Sponsor: Traditional Alternative Medicine Research, India
Phase classification: P4 --> P1 Initiation date: Feb 2017 --> Feb 2012
- | rifampicin / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Immune Activation and Drug Absorption in HIV-Infected Patients (clinicaltrials.gov) - Mar 3, 2017
P=N/A, N=7, Completed, Sponsor: Drexel University
Initiation date: Feb 2017 --> Feb 2012 Not yet recruiting --> Completed | N=10 --> 7 | Trial primary completion date: Dec 2014 --> Mar 2016
- | NN1213 / Novo Nordisk
Phase classification: A Novel Method to Determine HIV Incidence Among Youth (clinicaltrials.gov) - Mar 1, 2017
P=N/A, N=440, Completed, Sponsor: University of North Carolina, Chapel Hill
Not yet recruiting --> Completed | N=10 --> 7 | Trial primary completion date: Dec 2014 --> Mar 2016 Phase classification: P1/2 --> P=N/A
- | NN1213 / Novo Nordisk
Trial completion, Adherence: Typology of Adherence in Adolescents: Phase II (clinicaltrials.gov) - Feb 28, 2017
P2, N=1200, Completed, Sponsor: University of North Carolina, Chapel Hill
Phase classification: P1/2 --> P=N/A Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Connect to Protect Partnerships for Youth Prevention Interventions: Phase II (clinicaltrials.gov) - Feb 28, 2017
P2, N=16706, Completed, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: A Novel Method to Determine HIV Incidence Among Youth (clinicaltrials.gov) - Feb 28, 2017
P=N/A, N=440, Completed, Sponsor: University of North Carolina, Chapel Hill
No longer recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Healthy Choices to Promote Health and Reduce Risk in HIV-Infected Youth (clinicaltrials.gov) - Feb 28, 2017
P=N/A, N=225, Completed, Sponsor: University of North Carolina, Chapel Hill
No longer recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: 4-Day-A-Week Treatment Plan for HIV Infected Adolescents (clinicaltrials.gov) - Feb 28, 2017
P4, N=31, Completed, Sponsor: University of North Carolina, Chapel Hill
No longer recruiting --> Completed No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Metabolic Abnormalities in HIV Infected and Uninfected Young Women (clinicaltrials.gov) - Feb 28, 2017
P=N/A, N=300, Completed, Sponsor: University of North Carolina, Chapel Hill
No longer recruiting --> Completed Recruiting --> Completed
- | Enrollment change, Trial withdrawal: Impact of Anti-HIV Treatment on Labor Productivity and Costs in South Africa (clinicaltrials.gov) - Feb 28, 2017
P=N/A, N=0, Withdrawn, Sponsor: Boston University
Recruiting --> Completed N=120 --> 0 | Terminated --> Withdrawn
- | Phase classification: PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir (clinicaltrials.gov) - Feb 28, 2017
P=N/A, N=30, Completed, Sponsor: University of North Carolina, Chapel Hill
N=120 --> 0 | Terminated --> Withdrawn Phase classification: P4 --> P=N/A
- | NN1213 / Novo Nordisk
Phase classification: Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025 (clinicaltrials.gov) - Feb 28, 2017
P=N/A, N=337, Completed, Sponsor: University of North Carolina, Chapel Hill
Phase classification: P4 --> P=N/A Phase classification: P4 --> P=N/A
- | Trial completion, Trial initiation date: Traditional Complementary and Alternative Medicine (CAM) Therapy in the Treatment of HIV/AIDS (clinicaltrials.gov) - Feb 28, 2017
P3, N=1000, Completed, Sponsor: Traditional Alternative Medicine Research, India
Phase classification: P4 --> P=N/A Recruiting --> Completed | Initiation date: Mar 2012 --> Feb 2017
- | NN1213 / Novo Nordisk
Trial completion: Friendship Based HIV/STI (Sexually Transmitted Infections) Intervention for African American Females (clinicaltrials.gov) - Feb 27, 2017
P=N/A, N=420, Completed, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed | Initiation date: Mar 2012 --> Feb 2017 Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Evaluation of Genetic Markers as Explanations for the Observed Differences in Disease Progression in HIV+ Youth (clinicaltrials.gov) - Feb 27, 2017
P=N/A, N=113, Completed, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed No longer recruiting --> Completed
- | naltrexone / Generic mfg.
Trial completion, Trial primary completion date: WHATIF: Clinical Trial to Reduce Drinking in Women With HIV (clinicaltrials.gov) - Feb 27, 2017
P3, N=194, Completed, Sponsor: University of Florida
No longer recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Jul 2016
- ||| emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion, Enrollment change: A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication (clinicaltrials.gov) - Feb 24, 2017
P=N/A, N=99, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Jul 2016 Active, not recruiting --> Completed | N=400 --> 99
- ||||||| Isentress (raltegravir) / Merck (MSD)
Trial completion, Enrollment change, Trial primary completion date: Safety Study of Isentress (clinicaltrials.gov) - Feb 23, 2017
P3, N=149, Completed, Sponsor: Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux
Active, not recruiting --> Completed | N=400 --> 99 Not yet recruiting --> Completed | N=200 --> 149 | Trial primary completion date: Sep 2011 --> Aug 2012
- ||| Trial completion: Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=468, Completed, Sponsor: Gen-Probe, Incorporated
Not yet recruiting --> Completed | N=200 --> 149 | Trial primary completion date: Sep 2011 --> Aug 2012 Active, not recruiting --> Completed
- ||||||| Edurant (rilpivirine) / J&J, Prezcobix (darunavir/cobicistat) / Gilead, J&J, Intelence (etravirine) / J&J
Trial completion, Trial primary completion date: A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women (clinicaltrials.gov) - Feb 15, 2017
P3, N=77, Completed, Sponsor: Janssen Scientific Affairs, LLC
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: May 2017 --> Aug 2016
- Hiltonol (poly-ICLC) / Oncovir
Trial primary completion date: Enhancement by Poly-ICLC During HIV-1 Infection (clinicaltrials.gov) - Feb 14, 2017
P1/2, N=15, Active, not recruiting, Sponsor: Nina Bhardwaj
Recruiting --> Completed | Trial primary completion date: May 2017 --> Aug 2016 Trial primary completion date: Aug 2016 --> Apr 2017
- Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: Viral Biofilms: Hijacking T Cell Extracellular Matrix to Regulate HIV-1 Spread? (clinicaltrials.gov) - Feb 14, 2017
P=N/A, N=6, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Trial primary completion date: Aug 2016 --> Apr 2017 Recruiting --> Completed | N=20 --> 6 | Initiation date: Dec 2013 --> Jan 2013 | Trial primary completion date: Mar 2015 --> Dec 2014
- | NN1213 / Novo Nordisk
Trial completion: Anti-HIV Medications for People Recently Infected With HIV (clinicaltrials.gov) - Feb 6, 2017
P4, N=180, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | N=20 --> 6 | Initiation date: Dec 2013 --> Jan 2013 | Trial primary completion date: Mar 2015 --> Dec 2014 Recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Interluekin-7 to Treat HIV-Infected People Receiving Antiretroviral Treatment (clinicaltrials.gov) - Feb 6, 2017
P1, N=20, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Recruiting --> Completed
- ||||||| Invirase (saquinavir) / Roche
Trial completion: GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection (clinicaltrials.gov) - Feb 6, 2017
P3, N=337, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Trial primary completion date: CASA: Community-based Accompaniment With Supervised Antiretrovirals in Lima, Peru (clinicaltrials.gov) - Feb 3, 2017
P3, N=1244, Completed, Sponsor: Brigham and Women's Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Jul 2012
- Trial completion, Trial primary completion date: Tuberculosis Recurrence Upon Treatment With Highly Active Antiretroviral Therapy (clinicaltrials.gov) - Feb 2, 2017
P=N/A, N=402, Completed, Sponsor: Centre for the AIDS Programme of Research in South Africa
Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Jul 2012 Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Apr 2014
- | emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: IPERGAY: On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men (clinicaltrials.gov) - Feb 1, 2017
P3, N=400, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Apr 2014 Suspended --> Completed | N=1900 --> 400 | Trial primary completion date: Mar 2016 --> Jun 2016
- mefloquine / Generic mfg.
Trial completion: The Effect of Malaria on Disease Progression of HIV/AIDS (clinicaltrials.gov) - Jan 26, 2017
P=N/A, N=197, Completed, Sponsor: London School of Hygiene and Tropical Medicine
Suspended --> Completed | N=1900 --> 400 | Trial primary completion date: Mar 2016 --> Jun 2016 Active, not recruiting --> Completed
- methamphetamine / Generic mfg.
Trial completion, Trial primary completion date: Reduction of Drug Use and HIV Risk Among Out-of-Treatment Methamphetamine Users (clinicaltrials.gov) - Jan 23, 2017
P=N/A, N=502, Completed, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jun 2015
- NN1213 / Novo Nordisk
Enrollment change, Trial withdrawal: Use of Muscle Spectroscopy to Evaluate Mitochondrial Dysfunction in HIV-Infected Patients (clinicaltrials.gov) - Jan 19, 2017
P=N/A, N=0, Withdrawn, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jun 2015 N=32 --> 0 | Suspended --> Withdrawn
- Phase classification: A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults (clinicaltrials.gov) - Jan 19, 2017
P2b, N=130, Terminated, Sponsor: ViiV Healthcare
N=32 --> 0 | Suspended --> Withdrawn Phase classification: P2 --> P2b
- Trial primary completion date: RHIVA: Reducing HIV in Adolescents (clinicaltrials.gov) - Jan 19, 2017
P2, N=3217, Completed, Sponsor: Centre for the AIDS Programme of Research in South Africa
Phase classification: P2 --> P2b Trial primary completion date: Dec 2012 --> Aug 2014